about
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaaHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcome.[Thrombotic microangiopathy : Relevant new aspects for intensive care physicians].Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to EculizumabNephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome.A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic SyndromeHUS and atypical HUS.New milestones ahead in complement-targeted therapy.Eculizumab in secondary atypical haemolytic uraemic syndrome.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New ZealandComplement related kidney diseases: Recurrence after transplantation.Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.The complement system as a potential therapeutic target in rheumatic disease.Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies.Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.The Players: Cells Involved in Glomerular Disease.Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.Thrombotic microangiopathies: a general approach to diagnosis and management.Endothelial cells: source, barrier, and target of defensive mediators.Structural insight into proteolytic activation and regulation of the complement system.Complement factor H in host defense and immune evasion.Complementopathies.Many drugs for many targets: novel treatments for complement-mediated glomerular disease.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Liver involvement in kidney disease and vice versa.Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab.Complement in Non-Antibody-Mediated Kidney Diseases.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.All Things Complement.Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.The renaissance of complement therapeutics.
P2860
Q26739894-03057E88-F11F-4F63-AFF7-22FDCFCAAE12Q33427568-E7A588D3-C34E-47C7-8266-4E143E50C502Q33432677-A643A078-EFF5-4CFE-BCC2-662554FF33DAQ33436295-D67E329A-91FB-4CC4-8CAA-C881A02EF4D5Q33437259-2B1AF042-935C-436B-B884-7BE2CF3CBDA1Q33437634-0B4E77E0-7D2F-4014-88F2-56CED2B11CC9Q33441069-67E489C6-0BD6-4B48-9946-5C83717FFE93Q33602320-24DE4383-93A4-44AA-9656-7150114E6425Q33620588-E6A2C592-5664-4555-A71A-26313D96871AQ33783126-F39E22A6-7B15-4E04-8D13-EFE8A88067C1Q36553903-8EF5873C-718C-42FF-BEAB-081702C901F2Q36978838-83744B93-3E97-42A7-9F24-26D9CF56933DQ37480751-709DF890-CC3D-4058-85E0-D33D947A1C7CQ37522557-8710467F-22DA-4B3A-93C4-62D6741AF777Q37727489-CCCD2F94-4534-4FF7-9A2B-594AC978C5CFQ38631542-F6F09C8B-BFA1-49F6-B195-834690C92804Q38655720-4644CCFA-75FF-49DD-84D9-A3AB9A0540B0Q38770928-AA28376F-F4BF-4F4F-AD87-1CB10F70B2F1Q38846881-64CC9A07-BA8E-4857-B018-288579236143Q38864097-18B7BEC4-DD9A-4A11-BAA9-E68A1F048257Q38881874-EEEC4824-A3D9-4335-BAF2-D9E11090AD78Q38886279-0F32F390-3335-4946-8F53-86873A639195Q38907049-572AF5CA-F806-4237-B11C-404AE670AC90Q38984066-8CBDCAF0-2071-4EDA-AD6A-D4726D060CEFQ38991026-BF98CF06-578F-49E8-9E83-4D4123C861C0Q38991069-77D65D85-B21E-4E2C-AD5B-6D804FE3348BQ39036058-C912A895-A026-419F-B177-56E7A15F9C48Q39142842-48EBA191-1BC3-487C-9427-32C8C1A84F09Q39229285-D46CE3D9-CB29-42B0-AE04-A5494E1580E9Q39309248-E2F340CA-7FAD-4919-9D1C-0519623EA591Q39395392-F22BFC18-EFDA-4427-8F20-541D895D3CC8Q40231165-F0B8463A-92B7-4214-BFF5-7FFAB16656B0Q40593336-D0EA0118-EEF1-450E-A34A-83156C600296Q40986583-008400AD-45C7-4537-9330-D01E79751C5EQ42086661-117E5495-5CA3-4339-A22A-A53FE57FA1E5Q42386506-1558F739-8E04-4B32-A2F4-D8A7300AC21FQ47129863-BA67F8E2-4283-4B2E-B323-5FD3F359FF3DQ47225732-42ADDCDB-F0C9-428E-9A68-12149DC6317EQ47327197-F502BAAF-7D88-491B-A6B4-D4CC1C588DB6Q47336749-A873704F-801C-4ABD-9682-5A57B5AB6922
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Atypical aHUS: State of the art.
@ast
Atypical aHUS: State of the art.
@en
type
label
Atypical aHUS: State of the art.
@ast
Atypical aHUS: State of the art.
@en
prefLabel
Atypical aHUS: State of the art.
@ast
Atypical aHUS: State of the art.
@en
P2093
P50
P1433
P1476
Atypical aHUS: State of the art
@en
P2093
Carla M Nester
Christine Skerka
Marina Noris
Matthew Pickering
Santiago Rodriquez de Cordoba
Tim H J Goodship
Veronique Fremeaux-Bacchi
P356
10.1016/J.MOLIMM.2015.03.246
P50
P577
2015-04-03T00:00:00Z